In C3A and SNU-398, which exhibit high expression of PDGFRA, the combination of avapritinib and lenvatinib demonstrated a robust synergistic inhibitory effect on tumor cell growth (Fig. 3B). The gene discussed is PDGFRA; the disease is neoplasm.